| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obsessive-Compulsive Disorder | 138 | 2024 | 622 | 21.020 |
Why?
|
| Deep Brain Stimulation | 45 | 2023 | 348 | 8.080 |
Why?
|
| Anxiety Disorders | 26 | 2024 | 666 | 2.450 |
Why?
|
| Psychiatric Status Rating Scales | 29 | 2022 | 901 | 2.150 |
Why?
|
| Mental Disorders | 17 | 2023 | 862 | 2.100 |
Why?
|
| Tourette Syndrome | 14 | 2023 | 130 | 2.030 |
Why?
|
| Transcranial Magnetic Stimulation | 10 | 2023 | 75 | 2.000 |
Why?
|
| Psychometrics | 25 | 2023 | 937 | 1.910 |
Why?
|
| Emotions | 13 | 2023 | 562 | 1.730 |
Why?
|
| Connectome | 3 | 2023 | 112 | 1.530 |
Why?
|
| Surveys and Questionnaires | 31 | 2022 | 5687 | 1.520 |
Why?
|
| Implosive Therapy | 6 | 2020 | 75 | 1.470 |
Why?
|
| Brain | 20 | 2023 | 4113 | 1.420 |
Why?
|
| Parents | 17 | 2024 | 998 | 1.330 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 10 | 2022 | 231 | 1.330 |
Why?
|
| Adolescent | 87 | 2024 | 31252 | 1.270 |
Why?
|
| Anxiety | 21 | 2023 | 1179 | 1.220 |
Why?
|
| Streptococcal Infections | 6 | 2011 | 280 | 1.210 |
Why?
|
| Cerebral Cortex | 5 | 2018 | 621 | 1.190 |
Why?
|
| Tic Disorders | 6 | 2019 | 65 | 1.180 |
Why?
|
| Severity of Illness Index | 38 | 2022 | 4320 | 1.170 |
Why?
|
| Antipsychotic Agents | 7 | 2019 | 414 | 1.150 |
Why?
|
| Prefrontal Cortex | 11 | 2023 | 229 | 1.110 |
Why?
|
| Humans | 207 | 2024 | 261506 | 1.040 |
Why?
|
| Psychiatry | 2 | 2023 | 307 | 1.000 |
Why?
|
| Interoception | 3 | 2018 | 5 | 1.000 |
Why?
|
| Attention | 4 | 2019 | 281 | 0.990 |
Why?
|
| Nerve Net | 4 | 2021 | 257 | 0.990 |
Why?
|
| Subthalamic Nucleus | 3 | 2021 | 57 | 0.980 |
Why?
|
| Septal Nuclei | 1 | 2023 | 9 | 0.920 |
Why?
|
| Child | 72 | 2024 | 29154 | 0.920 |
Why?
|
| Depression | 18 | 2023 | 1715 | 0.890 |
Why?
|
| Depressive Disorder, Major | 9 | 2024 | 441 | 0.860 |
Why?
|
| Tics | 4 | 2010 | 48 | 0.840 |
Why?
|
| Fluoxetine | 4 | 2009 | 43 | 0.820 |
Why?
|
| Personality Inventory | 10 | 2010 | 178 | 0.820 |
Why?
|
| Emergency Shelter | 2 | 2019 | 8 | 0.820 |
Why?
|
| Internal Capsule | 6 | 2023 | 40 | 0.810 |
Why?
|
| Treatment Outcome | 51 | 2024 | 32848 | 0.770 |
Why?
|
| Streptococcus pyogenes | 4 | 2011 | 119 | 0.760 |
Why?
|
| Psychosurgery | 3 | 2023 | 28 | 0.760 |
Why?
|
| Male | 107 | 2024 | 123000 | 0.740 |
Why?
|
| Cycloserine | 4 | 2019 | 24 | 0.730 |
Why?
|
| Adult | 77 | 2023 | 77950 | 0.710 |
Why?
|
| Antidepressive Agents | 8 | 2018 | 332 | 0.690 |
Why?
|
| Female | 106 | 2024 | 141928 | 0.680 |
Why?
|
| Serotonin Antagonists | 1 | 2018 | 41 | 0.660 |
Why?
|
| Ondansetron | 1 | 2018 | 42 | 0.650 |
Why?
|
| Suicide | 5 | 2023 | 180 | 0.650 |
Why?
|
| Parkinson Disease | 6 | 2023 | 708 | 0.640 |
Why?
|
| Anhedonia | 4 | 2024 | 39 | 0.640 |
Why?
|
| Civil Defense | 1 | 2018 | 13 | 0.640 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2018 | 22 | 0.630 |
Why?
|
| Cognition | 6 | 2022 | 968 | 0.610 |
Why?
|
| Electroconvulsive Therapy | 2 | 2016 | 59 | 0.600 |
Why?
|
| Citalopram | 3 | 2005 | 36 | 0.580 |
Why?
|
| Factor Analysis, Statistical | 11 | 2019 | 356 | 0.580 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2023 | 92 | 0.580 |
Why?
|
| Olfactory Perception | 1 | 2017 | 31 | 0.580 |
Why?
|
| Reproducibility of Results | 20 | 2022 | 6009 | 0.570 |
Why?
|
| Disasters | 1 | 2018 | 107 | 0.570 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 207 | 0.550 |
Why?
|
| Interview, Psychological | 2 | 2013 | 98 | 0.540 |
Why?
|
| Nucleus Accumbens | 4 | 2010 | 61 | 0.530 |
Why?
|
| Comorbidity | 13 | 2024 | 2352 | 0.530 |
Why?
|
| Brain Mapping | 8 | 2023 | 644 | 0.530 |
Why?
|
| Signal Detection, Psychological | 2 | 2014 | 9 | 0.520 |
Why?
|
| Mental Health Services | 1 | 2018 | 227 | 0.520 |
Why?
|
| Hearing Disorders | 3 | 2023 | 29 | 0.510 |
Why?
|
| Visual Cortex | 1 | 2016 | 136 | 0.510 |
Why?
|
| Trichotillomania | 2 | 2014 | 32 | 0.510 |
Why?
|
| Family | 6 | 2022 | 736 | 0.500 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 129 | 0.500 |
Why?
|
| Cyclonic Storms | 3 | 2022 | 88 | 0.490 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2014 | 31 | 0.490 |
Why?
|
| Neurosciences | 2 | 2019 | 53 | 0.480 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2020 | 274 | 0.470 |
Why?
|
| Autoimmune Diseases | 2 | 2011 | 402 | 0.470 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 3 | 2008 | 41 | 0.460 |
Why?
|
| Depressive Disorder | 6 | 2016 | 557 | 0.460 |
Why?
|
| Behavior Therapy | 3 | 2020 | 298 | 0.450 |
Why?
|
| Quality of Life | 12 | 2023 | 4532 | 0.450 |
Why?
|
| Awareness | 2 | 2017 | 126 | 0.450 |
Why?
|
| Models, Neurological | 1 | 2014 | 225 | 0.450 |
Why?
|
| Thalamus | 3 | 2023 | 132 | 0.450 |
Why?
|
| Sertraline | 4 | 2015 | 45 | 0.440 |
Why?
|
| Neurosurgery | 3 | 2023 | 108 | 0.430 |
Why?
|
| Affect | 1 | 2014 | 288 | 0.430 |
Why?
|
| Habenula | 3 | 2018 | 44 | 0.420 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 78 | 0.420 |
Why?
|
| Survivors | 1 | 2018 | 1031 | 0.410 |
Why?
|
| Young Adult | 19 | 2022 | 21445 | 0.400 |
Why?
|
| Middle Aged | 43 | 2022 | 86204 | 0.390 |
Why?
|
| Artifacts | 3 | 2023 | 532 | 0.390 |
Why?
|
| Drug Discovery | 4 | 2010 | 324 | 0.380 |
Why?
|
| Adaptation, Psychological | 4 | 2021 | 764 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 7702 | 0.380 |
Why?
|
| Mental Health | 4 | 2023 | 415 | 0.370 |
Why?
|
| Neuropsychological Tests | 7 | 2017 | 1178 | 0.370 |
Why?
|
| Implantable Neurostimulators | 2 | 2020 | 18 | 0.370 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2024 | 604 | 0.360 |
Why?
|
| Attitude | 3 | 2020 | 159 | 0.350 |
Why?
|
| Gyrus Cinguli | 4 | 2023 | 140 | 0.350 |
Why?
|
| Child Behavior Disorders | 6 | 2009 | 68 | 0.340 |
Why?
|
| Smiling | 2 | 2010 | 16 | 0.340 |
Why?
|
| Combined Modality Therapy | 14 | 2021 | 8865 | 0.340 |
Why?
|
| Mood Disorders | 3 | 2023 | 163 | 0.320 |
Why?
|
| Health Status | 2 | 2009 | 590 | 0.320 |
Why?
|
| Psychology, Child | 2 | 2008 | 43 | 0.310 |
Why?
|
| Autism Spectrum Disorder | 3 | 2022 | 363 | 0.310 |
Why?
|
| Functional Laterality | 2 | 2010 | 316 | 0.310 |
Why?
|
| Double-Blind Method | 11 | 2021 | 2588 | 0.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 598 | 0.310 |
Why?
|
| Schizophrenia | 2 | 2008 | 369 | 0.300 |
Why?
|
| Family Health | 3 | 2019 | 325 | 0.300 |
Why?
|
| Reversal Learning | 2 | 2018 | 7 | 0.300 |
Why?
|
| Anorexia Nervosa | 2 | 2018 | 34 | 0.300 |
Why?
|
| Biomedical Research | 2 | 2019 | 806 | 0.300 |
Why?
|
| Politics | 2 | 2018 | 74 | 0.300 |
Why?
|
| Age Factors | 11 | 2019 | 5377 | 0.300 |
Why?
|
| Family Therapy | 1 | 2007 | 37 | 0.300 |
Why?
|
| Psychotic Disorders | 1 | 2008 | 147 | 0.290 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2006 | 6 | 0.290 |
Why?
|
| Neural Pathways | 3 | 2021 | 298 | 0.290 |
Why?
|
| Psychology, Adolescent | 1 | 2006 | 41 | 0.290 |
Why?
|
| Neurosurgical Procedures | 3 | 2023 | 609 | 0.290 |
Why?
|
| Adolescent Behavior | 3 | 2019 | 230 | 0.290 |
Why?
|
| Neuroimaging | 4 | 2023 | 403 | 0.290 |
Why?
|
| Brain Diseases | 2 | 2018 | 403 | 0.280 |
Why?
|
| Behavior | 1 | 2006 | 103 | 0.280 |
Why?
|
| Essential Tremor | 2 | 2023 | 85 | 0.280 |
Why?
|
| Drug Monitoring | 1 | 2008 | 333 | 0.270 |
Why?
|
| Benzodiazepines | 2 | 2004 | 170 | 0.270 |
Why?
|
| Imagination | 2 | 2016 | 21 | 0.270 |
Why?
|
| Telemedicine | 2 | 2022 | 471 | 0.270 |
Why?
|
| Caudate Nucleus | 2 | 2017 | 43 | 0.260 |
Why?
|
| Compulsive Behavior | 3 | 2011 | 36 | 0.260 |
Why?
|
| Radiosurgery | 3 | 2023 | 1330 | 0.260 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2018 | 14 | 0.260 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 259 | 0.250 |
Why?
|
| Intraoperative Period | 1 | 2004 | 246 | 0.240 |
Why?
|
| Drug Resistance | 4 | 2013 | 587 | 0.240 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 348 | 0.240 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2023 | 209 | 0.240 |
Why?
|
| Data Compression | 1 | 2023 | 14 | 0.230 |
Why?
|
| Analysis of Variance | 5 | 2014 | 2307 | 0.230 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2023 | 61 | 0.230 |
Why?
|
| Electromagnetic Fields | 2 | 2022 | 50 | 0.230 |
Why?
|
| Parturition | 1 | 2024 | 65 | 0.230 |
Why?
|
| Anti-Anxiety Agents | 1 | 2004 | 90 | 0.230 |
Why?
|
| Hyperacusis | 1 | 2022 | 4 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2006 | 576 | 0.220 |
Why?
|
| Child, Preschool | 11 | 2022 | 16273 | 0.220 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 918 | 0.210 |
Why?
|
| Reward | 1 | 2023 | 169 | 0.210 |
Why?
|
| Rheumatic Fever | 1 | 2002 | 18 | 0.210 |
Why?
|
| China | 5 | 2023 | 606 | 0.210 |
Why?
|
| Limbic System | 2 | 2013 | 29 | 0.200 |
Why?
|
| Antibodies, Bacterial | 1 | 2004 | 380 | 0.200 |
Why?
|
| Internal-External Control | 7 | 2019 | 110 | 0.200 |
Why?
|
| Angelman Syndrome | 1 | 2022 | 78 | 0.200 |
Why?
|
| Dystonia | 1 | 2023 | 163 | 0.200 |
Why?
|
| United Kingdom | 2 | 2020 | 257 | 0.200 |
Why?
|
| Treatment Failure | 4 | 2008 | 1391 | 0.200 |
Why?
|
| Electrophysiology | 1 | 2021 | 333 | 0.200 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 22 | 0.190 |
Why?
|
| Critical Care | 1 | 2007 | 770 | 0.190 |
Why?
|
| Self Report | 5 | 2023 | 756 | 0.190 |
Why?
|
| Conduct Disorder | 1 | 2020 | 26 | 0.190 |
Why?
|
| Personality Assessment | 4 | 2008 | 105 | 0.190 |
Why?
|
| Food | 2 | 2018 | 146 | 0.190 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 31 | 0.180 |
Why?
|
| Aged | 21 | 2022 | 70117 | 0.180 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2022 | 303 | 0.180 |
Why?
|
| Attitude to Health | 3 | 2009 | 465 | 0.180 |
Why?
|
| Faculty | 1 | 2021 | 130 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 164 | 0.180 |
Why?
|
| United States | 13 | 2023 | 15433 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2021 | 748 | 0.180 |
Why?
|
| Motivation | 3 | 2023 | 499 | 0.180 |
Why?
|
| Pyrrolidines | 1 | 2020 | 113 | 0.180 |
Why?
|
| Residential Treatment | 1 | 2019 | 12 | 0.180 |
Why?
|
| Photic Stimulation | 2 | 2015 | 259 | 0.180 |
Why?
|
| White Matter | 1 | 2022 | 195 | 0.170 |
Why?
|
| Behavioral Symptoms | 1 | 2019 | 32 | 0.170 |
Why?
|
| Anger | 1 | 2019 | 21 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2022 | 319 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2020 | 128 | 0.170 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 3719 | 0.170 |
Why?
|
| Touch Perception | 1 | 2018 | 20 | 0.170 |
Why?
|
| Perception | 1 | 2021 | 350 | 0.160 |
Why?
|
| Psychotherapy | 1 | 2021 | 247 | 0.160 |
Why?
|
| Neural Prostheses | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pandemics | 3 | 2022 | 1559 | 0.160 |
Why?
|
| Brain-Computer Interfaces | 1 | 2018 | 14 | 0.160 |
Why?
|
| Bioethics | 1 | 2019 | 70 | 0.160 |
Why?
|
| Habits | 1 | 2018 | 36 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 1648 | 0.160 |
Why?
|
| Data Mining | 1 | 2018 | 88 | 0.160 |
Why?
|
| Research Subjects | 1 | 2018 | 65 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2019 | 179 | 0.160 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 25 | 0.150 |
Why?
|
| Transportation of Patients | 1 | 2018 | 59 | 0.150 |
Why?
|
| Sensation | 1 | 2017 | 71 | 0.150 |
Why?
|
| N-Methylaspartate | 1 | 2017 | 50 | 0.150 |
Why?
|
| Checklist | 2 | 2022 | 122 | 0.150 |
Why?
|
| Cues | 1 | 2018 | 192 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 337 | 0.150 |
Why?
|
| Patient Preference | 1 | 2019 | 218 | 0.150 |
Why?
|
| Single-Blind Method | 2 | 2010 | 409 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 413 | 0.150 |
Why?
|
| Cytokines | 1 | 2006 | 2809 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2019 | 667 | 0.150 |
Why?
|
| Putamen | 1 | 2016 | 26 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2018 | 553 | 0.150 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2009 | 32 | 0.140 |
Why?
|
| Placebos | 3 | 2007 | 437 | 0.140 |
Why?
|
| Occipital Lobe | 1 | 2016 | 48 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 233 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 4938 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 399 | 0.130 |
Why?
|
| Epilepsy | 1 | 2023 | 883 | 0.130 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 69 | 0.130 |
Why?
|
| Observer Variation | 3 | 2007 | 671 | 0.130 |
Why?
|
| Myelin Sheath | 1 | 2016 | 149 | 0.130 |
Why?
|
| Avoidance Learning | 1 | 2015 | 94 | 0.130 |
Why?
|
| Psychophysics | 1 | 2014 | 19 | 0.130 |
Why?
|
| Amygdala | 1 | 2015 | 127 | 0.120 |
Why?
|
| Risk Factors | 8 | 2019 | 17523 | 0.120 |
Why?
|
| Benzamides | 1 | 2020 | 1832 | 0.120 |
Why?
|
| Chorea | 2 | 2006 | 34 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2019 | 674 | 0.120 |
Why?
|
| United States Food and Drug Administration | 4 | 2010 | 332 | 0.120 |
Why?
|
| Psychotropic Drugs | 2 | 2022 | 133 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2018 | 548 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 29902 | 0.120 |
Why?
|
| Fear | 1 | 2015 | 254 | 0.120 |
Why?
|
| International Cooperation | 1 | 2015 | 323 | 0.120 |
Why?
|
| Logistic Models | 5 | 2018 | 3441 | 0.120 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2010 | 75 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.120 |
Why?
|
| Reaction Time | 1 | 2014 | 234 | 0.110 |
Why?
|
| Parent-Child Relations | 2 | 2019 | 257 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 945 | 0.110 |
Why?
|
| Electrodes, Implanted | 3 | 2023 | 183 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 160 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2013 | 81 | 0.110 |
Why?
|
| Electrodes | 2 | 2023 | 116 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2013 | 154 | 0.110 |
Why?
|
| Suicide, Attempted | 3 | 2010 | 129 | 0.110 |
Why?
|
| Stereotaxic Techniques | 1 | 2013 | 172 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 1209 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2020 | 1270 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2008 | 1819 | 0.100 |
Why?
|
| Prevalence | 4 | 2007 | 3260 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2018 | 6100 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2013 | 2803 | 0.100 |
Why?
|
| Syndrome | 2 | 2022 | 1351 | 0.100 |
Why?
|
| Obsessive Behavior | 1 | 2011 | 16 | 0.100 |
Why?
|
| Statistics as Topic | 3 | 2007 | 445 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.090 |
Why?
|
| Judgment | 1 | 2010 | 47 | 0.090 |
Why?
|
| Laughter | 1 | 2010 | 12 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1371 | 0.090 |
Why?
|
| Child Behavior | 1 | 2012 | 243 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2013 | 574 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 14889 | 0.090 |
Why?
|
| Oxygen | 1 | 2014 | 754 | 0.090 |
Why?
|
| Caregivers | 3 | 2022 | 677 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 3472 | 0.090 |
Why?
|
| Prognosis | 6 | 2015 | 21713 | 0.090 |
Why?
|
| Propylamines | 1 | 2009 | 12 | 0.090 |
Why?
|
| Bacterial Proteins | 2 | 2006 | 1029 | 0.080 |
Why?
|
| Electroencephalography | 2 | 2023 | 898 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2010 | 12873 | 0.080 |
Why?
|
| Clomipramine | 2 | 2009 | 5 | 0.080 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2008 | 26 | 0.080 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.080 |
Why?
|
| Fluvoxamine | 2 | 2009 | 6 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 264 | 0.080 |
Why?
|
| Risperidone | 1 | 2009 | 62 | 0.080 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2008 | 7 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2010 | 497 | 0.080 |
Why?
|
| Compulsive Personality Disorder | 1 | 2008 | 12 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 32 | 0.080 |
Why?
|
| Drug Industry | 1 | 2008 | 88 | 0.080 |
Why?
|
| Therapies, Investigational | 1 | 2008 | 62 | 0.080 |
Why?
|
| Neurobiology | 1 | 2008 | 25 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 6311 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1945 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2023 | 1529 | 0.080 |
Why?
|
| Desensitization, Psychologic | 1 | 2007 | 6 | 0.080 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2008 | 59 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2008 | 187 | 0.070 |
Why?
|
| Feeding and Eating Disorders of Childhood | 1 | 2007 | 12 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2009 | 242 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 2315 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2010 | 376 | 0.070 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2006 | 19 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2024 | 37905 | 0.070 |
Why?
|
| Education | 1 | 2007 | 112 | 0.070 |
Why?
|
| Neuroanatomy | 1 | 2006 | 14 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 495 | 0.070 |
Why?
|
| Safety | 1 | 2008 | 465 | 0.070 |
Why?
|
| Patient Selection | 1 | 2014 | 2055 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2009 | 264 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 698 | 0.070 |
Why?
|
| Crime Victims | 1 | 2006 | 59 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 452 | 0.070 |
Why?
|
| Stress, Psychological | 3 | 2021 | 1000 | 0.070 |
Why?
|
| Amoxicillin | 1 | 2006 | 106 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 289 | 0.070 |
Why?
|
| Peer Group | 1 | 2006 | 133 | 0.070 |
Why?
|
| Animals | 6 | 2021 | 59536 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2020 | 1021 | 0.060 |
Why?
|
| Hydroxyzine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Streptolysins | 1 | 2004 | 7 | 0.060 |
Why?
|
| Buspirone | 1 | 2004 | 7 | 0.060 |
Why?
|
| Facial Expression | 1 | 2004 | 49 | 0.060 |
Why?
|
| Electroshock | 1 | 2004 | 46 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2004 | 25 | 0.060 |
Why?
|
| Deoxyribonucleases | 1 | 2004 | 46 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 435 | 0.060 |
Why?
|
| Carbohydrates | 1 | 2004 | 68 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2004 | 74 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 205 | 0.060 |
Why?
|
| Vagus Nerve | 1 | 2004 | 63 | 0.060 |
Why?
|
| Magnetics | 1 | 2004 | 107 | 0.060 |
Why?
|
| Computers | 1 | 2023 | 141 | 0.060 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.060 |
Why?
|
| Electromagnetic Radiation | 1 | 2022 | 4 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 116 | 0.050 |
Why?
|
| Light | 1 | 2023 | 245 | 0.050 |
Why?
|
| Psychophysiology | 1 | 2022 | 16 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2024 | 259 | 0.050 |
Why?
|
| Impulsive Behavior | 1 | 2023 | 142 | 0.050 |
Why?
|
| Ventral Striatum | 1 | 2021 | 19 | 0.050 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.050 |
Why?
|
| Basal Ganglia | 1 | 2002 | 64 | 0.050 |
Why?
|
| Algorithms | 2 | 2023 | 3890 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 397 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Health Surveys | 1 | 2023 | 402 | 0.050 |
Why?
|
| Psychotherapy, Group | 1 | 2021 | 59 | 0.050 |
Why?
|
| Functional Neuroimaging | 1 | 2020 | 38 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2020 | 20 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 53 | 0.050 |
Why?
|
| Behavior Observation Techniques | 1 | 2019 | 6 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 4744 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 5047 | 0.040 |
Why?
|
| Defense Mechanisms | 1 | 2019 | 22 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2021 | 100 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2019 | 23 | 0.040 |
Why?
|
| Family Relations | 1 | 2020 | 88 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 2010 | 276 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 67 | 0.040 |
Why?
|
| Problem Behavior | 1 | 2019 | 36 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sex Factors | 2 | 2019 | 2139 | 0.040 |
Why?
|
| Duty to Recontact | 1 | 2018 | 4 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 33 | 0.040 |
Why?
|
| Raphe Nuclei | 1 | 2018 | 35 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 436 | 0.040 |
Why?
|
| Somatosensory Cortex | 1 | 2018 | 68 | 0.040 |
Why?
|
| Dopaminergic Neurons | 1 | 2018 | 51 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2018 | 73 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2010 | 6869 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 160 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2010 | 414 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 1162 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 672 | 0.040 |
Why?
|
| Individuality | 1 | 2017 | 58 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 860 | 0.040 |
Why?
|
| Florida | 2 | 2008 | 113 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 4314 | 0.040 |
Why?
|
| Language | 1 | 2019 | 309 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 360 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 462 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 694 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2403 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2015 | 1171 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 71 | 0.030 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2015 | 14 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 1294 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2015 | 31 | 0.030 |
Why?
|
| Facial Muscles | 1 | 2015 | 51 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2016 | 125 | 0.030 |
Why?
|
| Electromyography | 1 | 2015 | 226 | 0.030 |
Why?
|
| Hippocampus | 1 | 2020 | 915 | 0.030 |
Why?
|
| Observation | 1 | 2014 | 48 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 1544 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 552 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 792 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1313 | 0.030 |
Why?
|
| Paliperidone Palmitate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2992 | 0.030 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 678 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 543 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 561 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 2594 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Pregnancy | 1 | 2024 | 7573 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 573 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 4971 | 0.020 |
Why?
|
| Connecticut | 1 | 2009 | 33 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 4892 | 0.020 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 16 | 0.020 |
Why?
|
| Government Programs | 1 | 2008 | 15 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 425 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 208 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2008 | 122 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2008 | 46 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1085 | 0.020 |
Why?
|
| Universities | 1 | 2008 | 160 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 1183 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 752 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2008 | 170 | 0.020 |
Why?
|
| Agonistic Behavior | 1 | 2006 | 10 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2007 | 114 | 0.020 |
Why?
|
| Loneliness | 1 | 2006 | 27 | 0.020 |
Why?
|
| Entropy | 1 | 2006 | 37 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2006 | 245 | 0.020 |
Why?
|
| Globus Pallidus | 1 | 2006 | 71 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2006 | 104 | 0.020 |
Why?
|
| Pharynx | 1 | 2006 | 153 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 418 | 0.020 |
Why?
|
| Seasons | 1 | 2006 | 340 | 0.020 |
Why?
|
| Public Health Administration | 1 | 2004 | 13 | 0.020 |
Why?
|
| Social Behavior | 1 | 2006 | 306 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 482 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2004 | 203 | 0.010 |
Why?
|
| Drug Approval | 1 | 2004 | 178 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 2002 | 10 | 0.010 |
Why?
|
| Parenting | 1 | 2007 | 345 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 208 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 556 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2003 | 134 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 305 | 0.010 |
Why?
|
| Nausea | 1 | 2003 | 525 | 0.010 |
Why?
|
| Skull | 1 | 2002 | 231 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 786 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 509 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2003 | 554 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 830 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 1301 | 0.010 |
Why?
|